Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine.

[1]  A. Bilbao,et al.  Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain , 2007, PAIN®.

[2]  R. Capasso,et al.  Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β‐cells , 2007 .

[3]  Didier Bagnol,et al.  A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. , 2007, Endocrinology.

[4]  S. Rapoport,et al.  Altered brain lipid composition in cyclooxygenase-2 knockout mouse Published, JLR Papers in Press, January 3, 2007. , 2007, Journal of Lipid Research.

[5]  S. Gaetani,et al.  Food Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small Intestine* , 2007, Journal of Biological Chemistry.

[6]  M. Itakura,et al.  Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. , 2006, Biochemical and biophysical research communications.

[7]  Stephen P. H. Alexander,et al.  Cannabinoids and PPARα signalling , 2006 .

[8]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[9]  B. Cravatt,et al.  Endocannabinoid Biosynthesis Proceeding through Glycerophospho-N-acyl Ethanolamine and a Role for α/β-Hydrolase 4 in This Pathway* , 2006, Journal of Biological Chemistry.

[10]  Bill X. Huang,et al.  A biosynthetic pathway for anandamide , 2006, Proceedings of the National Academy of Sciences.

[11]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[12]  Saori Oka,et al.  Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. , 2006, Progress in lipid research.

[13]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[14]  A. Saghatelian,et al.  Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. , 2006, Biochemistry.

[15]  C. Reynet,et al.  Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. , 2006, Cell metabolism.

[16]  P. J. Larsen,et al.  Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. , 2006, Biochimica et biophysica acta.

[17]  F. Bermúdez-Silva,et al.  Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell , 2006 .

[18]  D. Piomelli,et al.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.

[19]  V. Chapman,et al.  Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat , 2005, Pain.

[20]  B. Birnir,et al.  Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.

[21]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[22]  S. Gaetani,et al.  Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats , 2005, Neuropharmacology.

[23]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[24]  G. Ahern,et al.  Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short‐term food intake in mice via capsaicin receptor TRPV1 , 2005, The Journal of physiology.

[25]  H. Matsushime,et al.  Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. , 2005, Biochemical and biophysical research communications.

[26]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[27]  A. Izzo,et al.  The gastrointestinal pharmacology of cannabinoids: an update. , 2004, Current opinion in pharmacology.

[28]  M. Fabris,et al.  Stearoylethanolamide exerts anorexic effects in mice via downregulation of liver stearoyl‐coenzyme A desaturase‐1 mRNA expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  D. Piomelli,et al.  Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)* , 2004, Journal of Biological Chemistry.

[30]  M. Murakami,et al.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. , 2004, The Biochemical journal.

[31]  A. Astrup,et al.  Food intake is inhibited by oral oleoylethanolamide Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.C300008-JLR200 , 2004, Journal of Lipid Research.

[32]  S. Gaetani,et al.  Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. , 2004, Pharmacological research.

[33]  J. Angus,et al.  Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat , 2004, Pain.

[34]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[35]  P. Hornby,et al.  Involvement of cannabinoid receptors in gut motility and visceral perception , 2004, British journal of pharmacology.

[36]  D. Thompson,et al.  Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin , 2004, The Journal of Neuroscience.

[37]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[38]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[39]  A. J. Hulbert,et al.  Life, death and membrane bilayers , 2003, Journal of Experimental Biology.

[40]  P. Hornby,et al.  Cannabinoid1 Receptor in the Dorsal Vagal Complex Modulates Lower Oesophageal Sphincter Relaxation in Ferrets , 2003, The Journal of physiology.

[41]  T. Hamazaki,et al.  n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[42]  M. Reitman,et al.  Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. , 2003, Diabetes.

[43]  L. Marnett,et al.  Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. , 2003, Analytical biochemistry.

[44]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[45]  David Robbe,et al.  Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  V. Marzo,et al.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.

[47]  R. Capasso,et al.  Endocannabinoids and the gut. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[48]  K. Waku,et al.  Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[49]  A. Izzo,et al.  The gastrointestinal pharmacology of cannabinoids. , 2001, Current opinion in pharmacology.

[50]  S. Gaetani,et al.  An anorexic lipid mediator regulated by feeding , 2001, Nature.

[51]  T. Bisogno,et al.  Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Michaelsen,et al.  The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. , 2001, Progress in lipid research.

[53]  S. Hansen,et al.  Accumulation of the anandamide precursor and other N‐acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death , 2001, Journal of neurochemistry.

[54]  H. Hansen,et al.  N-Acylethanolamines and precursor phospholipids - relation to cell injury. , 2000, Chemistry and physics of lipids.

[55]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[56]  D. Piomelli,et al.  Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. , 2000, Analytical biochemistry.

[57]  J. Chambers,et al.  The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.

[58]  M. Lagarde,et al.  Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. , 1999, Archives of biochemistry and biophysics.

[59]  J. Manzanares,et al.  Identification of Endocannabinoids and Cannabinoid CB1 Receptor mRNA in the Pituitary Gland , 1999, Neuroendocrinology.

[60]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[61]  S. Bowman,et al.  Dietary-fat intake in the US population. , 1999, Journal of the American College of Nutrition.

[62]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[63]  K. Waku,et al.  Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor , 1999, The Journal of Biological Chemistry.

[64]  S. Yamamoto,et al.  A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. , 1998, The journal of medical investigation : JMI.

[65]  K. Waku,et al.  Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. , 1998, Archives of biochemistry and biophysics.

[66]  L. Petrocellis,et al.  The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. , 1998, The Biochemical journal.

[67]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[68]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[69]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[70]  G. Pascal,et al.  Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. , 1992, Biochimica et biophysica acta.

[71]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[72]  K. Georgeson,et al.  Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[73]  P. Kris-Etherton,et al.  Polyunsaturated fatty acids in the food chain in the United States. , 2000, The American journal of clinical nutrition.

[74]  H Kesteloot,et al.  Intake of fatty acids in Western Europe with emphasis on trans fatty acids: The TRANSFAIR study , 1999, European Journal of Clinical Nutrition.

[75]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[76]  H. Schmid,et al.  N-acylated glycerophospholipids and their derivatives. , 1990, Progress in lipid research.